Try our beta test site
Trial record 1 of 1 for:    ND0612H-012
Previous Study | Return to List | Next Study

A Clinical Study Investigating Long Term Safety of ND0612, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by NeuroDerm Ltd.
Information provided by (Responsible Party):
NeuroDerm Ltd. Identifier:
First received: March 29, 2016
Last updated: February 23, 2017
Last verified: September 2016
This is a multi-center, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa (LD/CD) delivered via a pump system as a continuous SC infusion in subjects with advanced Parkinson's Disease.

Condition Intervention Phase
Parkinson's Disease
Drug: ND0612
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease

Resource links provided by NLM:

Further study details as provided by NeuroDerm Ltd.:

Primary Outcome Measures:
  • Assess the long term safety (systemic and local) and tolerability of continuous subcutaneous infusion of ND0612 by adverse events, vital signs, local tolerability [ Time Frame: 12 month ]

Estimated Enrollment: 100
Study Start Date: May 2016
Estimated Study Completion Date: May 2018
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ND0612 (Levodopa/Carbidopa solution) - Regimen 1
Regimen 1 of ND0612 (LD/CD solution) continuous subcutaneous infusion over 24 hrs
Drug: ND0612
ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
Experimental: ND0612 (Levodopa/Carbidopa solution) - Regimen 2
Regimen 2 of ND0612 (LD/CD solution) continuous subcutaneous for over 14-16 hrs .
Drug: ND0612
ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system

Detailed Description:
This phase open-label safety study will be conducted in approximately 100 subjects.

Ages Eligible for Study:   30 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female ,Parkinson's disease subjects of any race aged 30 to 85 years .
  • PD diagnosis consistent with the UK Brain Bank Criteria.
  • Modified Hoehn & Yahr scale in "ON" state of stage ≤3.
  • Taking at least 4 doses/day of Levodopa (or at least 3 doses/day of Rytary) and taking, or have attempted to take, at least 1 other Parkinson's disease treatment for at least 30 days in the previous year.
  • Subjects must be stable on their anti-Parkinson's disease medications for at least 30 days before Day 1.
  • Subjects may have had prior exposure to Sub Cutaneous apomorphine injections/infusion but must have stopped administration at least 4 weeks before the screening visit. Treatment with apomorphine is prohibited during the entire ND0612 treatment period.
  • Must have a minimum of 2 hours of "OFF" time per day with predictable early morning "OFF" periods as estimated by the subject.
  • Must have predictable and well defined early morning "OFF" periods with a good response to Levodopa for treatment of the early morning "OFF" in the judgement of the investigator.
  • Mini Mental State Examination (MMSE) score >26.
  • No clinically significant medical, psychiatric or laboratory abnormalities which the investigator judges would be unsafe or non-compliant in the study.
  • Female subjects must be surgically sterile (hysterectomy, bilateral oophorectomy, or tubal ligation), postmenopausal (defined as cessation of menses for at least 1 year), or willing to practice a highly effective method of contraception. All female participants must be non-lactating and non-pregnant and have a negative urine pregnancy test at Screening and at Baseline. Female subjects of childbearing potential must practice a highly effective method of contraception ( oral contraceptives plus a barrier method of birth control [condoms with contraceptive foams, diaphragms with contraceptive jelly], intrauterine devices, partner with vasectomy), 1 month before enrollment, for the duration of the study, and 3 months after the last dose of study drug.
  • Willing and able to administer the subcutaneous infusion alone or with the assistance of a study partner after a screening period of 28 days and willing and able to comply with study requirements.

Exclusion Criteria:

For Cohort 1 and Cohort 2, the following exclusion criterion applies:

  • Previously unable to tolerate ND0612 and/or have experienced intolerable adverse drug reactions associated with its use, regardless of the dosing regimen administered.

For Cohort 2, the following exclusion criteria apply:

  • Atypical or secondary parkinsonism.
  • Acute psychosis or hallucinations in past 6 months.
  • Any relevant medical, surgical, or psychiatric condition, laboratory value, or concomitant medication which, in the opinion of the Investigator makes the subject unsuitable for study entry or potentially unable to complete all aspects of the study.
  • Prior neurosurgical procedure for Parkinson's disease, or duodopa treatment.
  • Subjects with a history of drug abuse or alcoholism within the past 12 months.
  • Clinically significant ECG rhythm abnormalities.
  • Renal or liver dysfunction that may alter drug metabolism including: serum creatinine >1.3 mg/dL, serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 x upper limit of normal (ULN), total serum bilirubin >2.5 mg/dL.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02726386

Contact: Yael Ullmann +972-8-9462729
Contact: Yael Cohen +972-8-9462729

United States, California
Neuro Pain Medical Center Recruiting
Fresno, California, United States, 93710
Contact: Perminder Bhatia    559-437-9700   
Contact: Isha Monga Harpreet    559-347-9700   
United States, Colorado
Rocky Mountain Movement Disorders Center Recruiting
Englewood, Colorado, United States, 80113-2776
Contact: Rajeev Kumar, Dr.    303-357-5455   
Contact: Peggy Hugger    303 867 5468   
United States, Florida
MD Clinical Recruiting
Hallandale Beach, Florida, United States, 33009
Contact: Beth Safirstein, Dr.    954-455-5757   
Contact: William Torres    954-455-5757   
Infinity Clinical Research, LLC Recruiting
Hollywood, Florida, United States, 33021
Contact: Paul Ginsberg, Dr.    954-366-0277   
Contact: Becky Nembhard    954-366-0277   
Neurology Associates, PA Recruiting
Maitland, Florida, United States, 32751-4723
Contact: Arnaldo Isa, Dr.    407-647-5996 ext 236   
Contact: Kelly Holley    407-647-5996 ext 204   
Parkinsons Disease Treatment Center of Southwest Florida Recruiting
Port Charlotte, Florida, United States, 33980
Contact: Ramon Gil, Dr.    941-743-4987   
Contact: Judy Seymour    941-743-4987   
Suncoast Neuroscience Associates Recruiting
St. Petersburg, Florida, United States, 33713-8844
Contact: Alberto Vasquez, Dr.    727-202-2623   
Contact: Ian Lever    727-202-2640   
Infinity Clinical Research, LLC Recruiting
Sunrise, Florida, United States, 33351
Contact: Barry Cutler, Dr.    954-475-8171   
Contact: Fanny Gully    954-475-8171   
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Tanya Simuni, Dr.   
Contact: Karen Williams    312 503 5645   
United States, Michigan
QUEST Research Institute Recruiting
Farmington Hills, Michigan, United States, 48334
Contact: Aaron Ellenbogen, Dr.    248-957-8940   
Contact: Dolly Niles    248-957-8940   
United States, New Jersey
Pyramid Clinical Research Recruiting
Somerset, New Jersey, United States, 08873-3448
Contact: Jeffrey Greenberg, Dr.    844-255-1721   
Contact: Jillian Long    844-255-1721   
United States, Ohio
University of Cincinnati Recruiting
Cincinnati, Ohio, United States, 45267
Contact: Alberto Espay, Dr.    513-558-4035   
Contact: Molly Winters    513-558-0269   
United States, Oklahoma
The Movement Disorder Clinic of Oklahoma Recruiting
Tulsa, Oklahoma, United States, 74136
Contact: Kevin Klos    918-392-4530   
Contact: Shannon Gurley    918-392-4530   
United States, Virginia
Synergy Trials Recruiting
Richmond, Virginia, United States, 23226
Contact: Cletus Aralu, Dr.   
Contact: Ritha Khleang    804-405-4140   
Medical University Innsbruck Recruiting
Innsbruck, Austria, 6020
Contact: Werner Poewe, Prof.    0043 512 504 23850   
Contact: Katarzyna Wachowicz    0043 512 504 23850   
Kliniken Beelitz GmbH Recruiting
Beelitz Heilstaetten, Germany, 14547
Contact: Georg Ebersbach, Prof.    0049 33204-22781   
Contact: Karl Rowena    0049 33204-22781   
Rabin Medical Center Recruiting
Petah Tikva, Israel, 49100
Contact: Ruth Djaldetti, Prof.    972-3-9377154   
Contact: Yaniv Rodity, Mr.    972-3-6528734   
Chaim Sheba Medical Center Recruiting
Ramat Gan, Israel, 56520
Contact: Sharon Hassin, Prof.    972-3-5905293   
Contact: Patricia Federman    972-3-5304931   
Sourasky Medical Center Recruiting
Tel Aviv, Israel, 64239
Contact: Tanya Gurevich, Dr.    972-3-6974912   
Contact: Angel Migirov, M.    972-3-6973001   
University Foundation Recruiting
Chieti Scalo, Italy, 66100
Contact: Marco Onofrj, prof.    0039 0871 358525   
Contact: Thomas Astrid, Prof.    0039 3286537740   
AOU Pisa Recruiting
Pisa, Italy, 56126
Contact: Ubaldo Bonuccelli, Prof.    0039 050993604   
Contact: Pierangela Riani, Ms.    0039 3403134789   
IRCCS San Raffaele Pisana Recruiting
Rome, Italy, 00163
Contact: Fabrizio Stocchi, Prof.    0039 06 52252311   
Contact: Miriam Casali    0039 06 52252311   
IRCCS Hospital San Camillo Venice Recruiting
Venice, Italy, 30126
Contact: Angelo Antonini, Prof.    0039 4122073765   
Contact: Nicolò Anesa, Mr.    0039 0412207505   
Sponsors and Collaborators
NeuroDerm Ltd.
  More Information

Responsible Party: NeuroDerm Ltd. Identifier: NCT02726386     History of Changes
Other Study ID Numbers: ND0612H-012
Study First Received: March 29, 2016
Last Updated: February 23, 2017

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Pharmaceutical Solutions
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Aromatic Amino Acid Decarboxylase Inhibitors
Enzyme Inhibitors processed this record on March 23, 2017